Jerusalem Pharmaceuticals

Executive Summary

Jerusalem Pharmaceuticals is a private Israeli biotech company founded in 2020, dedicated to discovering and developing novel small-molecule and biologic therapeutics for oncology and immunology indications. Leveraging a proprietary target-identification and drug-design platform, the firm aims to address unmet medical needs with differentiated candidates. Currently in the preclinical stage, the company has built a robust pipeline and is advancing its lead programs towards IND-enabling studies. The management team combines deep scientific expertise and industry experience, positioning the company for potential value creation through strategic partnerships and future clinical development. Although early-stage, Jerusalem Pharmaceuticals represents an emerging player in the competitive biotech landscape, with a clear focus on high-unmet-need areas.

Upcoming Catalysts (preview)

• H2 2026IND Filing for Lead Oncology Program60% success
• H1 2026Series A or B Financing Round70% success
• 2026Preclinical Data Presentation at Major Conference80% success